Phosphagenics appoints consultant for promoting drug delivery tech
Phosphagenics (ASX:POH) has engaged the services of Dr Steve Meller to assist the company in partnering its TPM (Targeted Penetration Matrix) drug delivery technology with large companies selling into the mass market.
A graduate of The University of Adelaide, Dr Meller worked for about 20 years in senior global health, innovation and sustainability roles at Procter and Gamble (P&G) and now runs a specialty consulting company based in Silicon Valley. In this capacity he has been an adviser to companies across the globe.
Dr Meller will work closely with Phosphagenics to promote its technology to prospective partners, with a focus on the pharmaceutical and consumer health markets. Dr Meller said there is “a wide range of potential partners” who could be interested in the platform technology, which is said to enhance “dermal and transdermal delivery of drugs and other molecules”.
Phosphagenics CEO Dr Ross Murdoch said Dr Meller’s track record “speaks for itself”.
“His deep personal global networks, his experience in building and negotiating deals, combined with our technology and the considerable data supporting it, make a strong combination when looking for partners in mass markets,” he said.
Phosphagenics (ASX:POH) shares were trading 4.35% lower at $0.022 as of around 12.30 pm on Tuesday.
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
